vs

Side-by-side financial comparison of CPI AEROSTRUCTURES INC (CVU) and STANDARD BIOTOOLS INC. (LAB). Click either name above to swap in a different company.

STANDARD BIOTOOLS INC. is the larger business by last-quarter revenue ($19.6M vs $19.4M, roughly 1.0× CPI AEROSTRUCTURES INC). CPI AEROSTRUCTURES INC runs the higher net margin — 3.6% vs -177.4%, a 181.0% gap on every dollar of revenue. On growth, CPI AEROSTRUCTURES INC posted the faster year-over-year revenue change (-10.8% vs -11.5%). CPI AEROSTRUCTURES INC produced more free cash flow last quarter ($-2.1M vs $-23.1M). Over the past eight quarters, CPI AEROSTRUCTURES INC's revenue compounded faster (0.9% CAGR vs -12.2%).

CPI Aerostructures Inc., known as CPI Aero, is a contract aircraft component manufacturer based in Edgewood, New York.

Standard BioTools Inc., previously known as Fluidigm Corp., is an American life science tools company that offers analytical mass cytometry systems for flow cytometry and tissue imaging, along with associated assays and reagents, as well as an automated genomic analysis instrument and a variety of microfluidic arrays, or integrated fluidic circuits (IFCs), and consumables with fully kitted reagents. Custom assays and services are available with all systems and applications.

CVU vs LAB — Head-to-Head

Bigger by revenue
LAB
LAB
1.0× larger
LAB
$19.6M
$19.4M
CVU
Growing faster (revenue YoY)
CVU
CVU
+0.7% gap
CVU
-10.8%
-11.5%
LAB
Higher net margin
CVU
CVU
181.0% more per $
CVU
3.6%
-177.4%
LAB
More free cash flow
CVU
CVU
$21.0M more FCF
CVU
$-2.1M
$-23.1M
LAB
Faster 2-yr revenue CAGR
CVU
CVU
Annualised
CVU
0.9%
-12.2%
LAB

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CVU
CVU
LAB
LAB
Revenue
$19.4M
$19.6M
Net Profit
$691.8K
$-34.7M
Gross Margin
20.3%
48.5%
Operating Margin
6.4%
-168.5%
Net Margin
3.6%
-177.4%
Revenue YoY
-10.8%
-11.5%
Net Profit YoY
-28.8%
-28.8%
EPS (diluted)
$0.04
$-0.09

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVU
CVU
LAB
LAB
Q4 25
$19.4M
Q3 25
$19.3M
$19.6M
Q2 25
$15.2M
$21.8M
Q1 25
$15.4M
$40.8M
Q4 24
$21.8M
Q3 24
$19.4M
$22.1M
Q2 24
$20.8M
$22.5M
Q1 24
$19.1M
$45.5M
Net Profit
CVU
CVU
LAB
LAB
Q4 25
$691.8K
Q3 25
$1.1M
$-34.7M
Q2 25
$-1.3M
$-33.5M
Q1 25
$-1.3M
$-26.0M
Q4 24
$971.5K
Q3 24
$749.7K
$-26.9M
Q2 24
$1.4M
$-45.7M
Q1 24
$168.2K
$-32.2M
Gross Margin
CVU
CVU
LAB
LAB
Q4 25
20.3%
Q3 25
22.3%
48.5%
Q2 25
4.4%
48.8%
Q1 25
10.7%
48.4%
Q4 24
20.0%
Q3 24
21.7%
54.9%
Q2 24
24.6%
46.1%
Q1 24
18.6%
53.1%
Operating Margin
CVU
CVU
LAB
LAB
Q4 25
6.4%
Q3 25
9.1%
-168.5%
Q2 25
-13.1%
-118.1%
Q1 25
-7.7%
-80.8%
Q4 24
9.5%
Q3 24
7.6%
-120.9%
Q2 24
11.2%
-134.5%
Q1 24
4.4%
-132.2%
Net Margin
CVU
CVU
LAB
LAB
Q4 25
3.6%
Q3 25
5.8%
-177.4%
Q2 25
-8.7%
-153.7%
Q1 25
-8.6%
-63.8%
Q4 24
4.5%
Q3 24
3.9%
-122.0%
Q2 24
6.8%
-203.3%
Q1 24
0.9%
-70.6%
EPS (diluted)
CVU
CVU
LAB
LAB
Q4 25
$0.04
Q3 25
$0.09
$-0.09
Q2 25
$-0.10
$-0.09
Q1 25
$-0.10
$-0.07
Q4 24
$0.08
Q3 24
$0.06
$-0.07
Q2 24
$0.11
$-0.12
Q1 24
$0.01
$-0.27

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVU
CVU
LAB
LAB
Cash + ST InvestmentsLiquidity on hand
$129.4M
Total DebtLower is stronger
$0
Stockholders' EquityBook value
$25.8M
$399.7M
Total Assets
$75.2M
$539.6M
Debt / EquityLower = less leverage
0.00×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVU
CVU
LAB
LAB
Q4 25
Q3 25
$129.4M
Q2 25
$158.6M
Q1 25
$150.9M
Q4 24
Q3 24
$210.6M
Q2 24
$269.8M
Q1 24
$287.1M
Total Debt
CVU
CVU
LAB
LAB
Q4 25
$0
Q3 25
Q2 25
Q1 25
Q4 24
$26.5K
Q3 24
$55.2M
Q2 24
$55.1M
Q1 24
$55.0M
Stockholders' Equity
CVU
CVU
LAB
LAB
Q4 25
$25.8M
Q3 25
$25.0M
$399.7M
Q2 25
$23.8M
$424.5M
Q1 25
$24.9M
$454.6M
Q4 24
$25.9M
Q3 24
$24.9M
$489.3M
Q2 24
$24.1M
$510.3M
Q1 24
$22.5M
$577.3M
Total Assets
CVU
CVU
LAB
LAB
Q4 25
$75.2M
Q3 25
$74.1M
$539.6M
Q2 25
$72.3M
$557.0M
Q1 25
$65.4M
$579.6M
Q4 24
$68.0M
Q3 24
$68.9M
$681.5M
Q2 24
$70.2M
$708.7M
Q1 24
$70.8M
$777.7M
Debt / Equity
CVU
CVU
LAB
LAB
Q4 25
0.00×
Q3 25
Q2 25
Q1 25
Q4 24
0.00×
Q3 24
0.11×
Q2 24
0.11×
Q1 24
0.10×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVU
CVU
LAB
LAB
Operating Cash FlowLast quarter
$-2.1M
$-22.2M
Free Cash FlowOCF − Capex
$-2.1M
$-23.1M
FCF MarginFCF / Revenue
-10.8%
-118.1%
Capex IntensityCapex / Revenue
0.0%
4.5%
Cash ConversionOCF / Net Profit
-3.03×
TTM Free Cash FlowTrailing 4 quarters
$-5.3M
$-111.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVU
CVU
LAB
LAB
Q4 25
$-2.1M
Q3 25
$212.1K
$-22.2M
Q2 25
$-596.3K
$-20.7M
Q1 25
$-2.7M
$-30.3M
Q4 24
$4.4M
Q3 24
$715.1K
$-27.9M
Q2 24
$-591.7K
$-39.0M
Q1 24
$-960.5K
$-62.5M
Free Cash Flow
CVU
CVU
LAB
LAB
Q4 25
$-2.1M
Q3 25
$211.1K
$-23.1M
Q2 25
$-599.8K
$-22.6M
Q1 25
$-2.8M
$-35.3M
Q4 24
$4.3M
Q3 24
$586.9K
$-30.1M
Q2 24
$-746.9K
$-41.0M
Q1 24
$-1.0M
$-63.3M
FCF Margin
CVU
CVU
LAB
LAB
Q4 25
-10.8%
Q3 25
1.1%
-118.1%
Q2 25
-4.0%
-103.6%
Q1 25
-18.1%
-86.6%
Q4 24
19.9%
Q3 24
3.0%
-136.4%
Q2 24
-3.6%
-182.2%
Q1 24
-5.3%
-138.9%
Capex Intensity
CVU
CVU
LAB
LAB
Q4 25
0.0%
Q3 25
0.0%
4.5%
Q2 25
0.0%
8.7%
Q1 25
0.4%
12.4%
Q4 24
0.3%
Q3 24
0.7%
10.2%
Q2 24
0.7%
8.6%
Q1 24
0.2%
1.7%
Cash Conversion
CVU
CVU
LAB
LAB
Q4 25
-3.03×
Q3 25
0.19×
Q2 25
Q1 25
Q4 24
4.53×
Q3 24
0.95×
Q2 24
-0.42×
Q1 24
-5.71×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CVU
CVU

Government Subcontracts$16.4M85%
Commercial Contracts$2.3M12%
Prime Government Contracts$725.8K4%

LAB
LAB

Consumables$8.7M45%
Services And Other Revenue$5.8M29%
Instruments$5.1M26%

Related Comparisons